Simpson I A, Lorimer A R, Walker I D, Davidson J F
Thromb Haemost. 1985 Aug 30;54(2):442-4.
The fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients. We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.
对一种新型降脂药物环丙贝特的纤溶和血小板作用进行了为期12周的研究，研究对象为7例高胆固醇血症患者。结果发现血浆纤维蛋白原显著降低，纤溶活性增加较少。然而，未观察到血小板聚集有变化。正如预期的那样，环丙贝特在这些患者中产生了显著的降血脂作用。我们已经描述了环丙贝特的作用，这些作用可能对这一高危患者群体有潜在益处。
